RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000059.xml
Pneumologie 1999; 53(11): 521-529
DOI: 10.1055/s-1999-9244
DOI: 10.1055/s-1999-9244
ÜBERSICHT
Georg Thieme Verlag Stuttgart ·New YorkFluorchinolone zur Therapie von Atemwegsinfektionen[1]
Pharmakologisch-toxikologische AspekteWeitere Informationen
Publikationsverlauf
Publikationsdatum:
31. Dezember 1999 (online)
Fluorchinolone werden in zunehmendem Maße zur Therapie bakterieller Infektionen der Atemwege eingesetzt. Der Grund für diese Tendenz liegt in der Entwicklung neuer Chinolone, die eine gute bis sehr gute Aktivität gegen Pneumokokken und andere häufige Erreger von Atemwegsinfektionen aufweisen. Dadurch unterscheiden sie sich von den seit langem bekannten Chinolonen wie Ofloxacin und Ciprofloxacin, deren Stärke vor allem im gramnegativen Bereich des bakteriellen Spektrums liegt.
Literatur
- 1 Naber K G, Adam D. Classification of fluoroquinolones. Int J Antimicrob Agents. 1998; 10 255-257
- 2 Takahata M, Mitsuyama J, Yamashiro Y, Yonezawa M, Araki H, Todo Y, Minami S, Watanabe Y, Narita H. In vitro and in vivo antimicrobial activities of T-3811 ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother. 1999; 43 1077-1084
- 3 MacGowan A P, Bowker K E, Wootton M, Holt H A. Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection. Antimicrob Agents Chemother. 1999; 43 1560-1564
- 4 Drusano G L, Johnson D E, Rosen M, Standiford H C. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993; 37 483-490
- 5 Forrest A, Ballow C H, Nix D E, Birmingham M C, Schentag J J. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother. 1993a; 37 1065-1072
- 6 Forrest A, Nix D E, Ballow C H, Goss T F, Birmingham M C, Schentag J J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993b; 37 1073-1081
- 7 Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis. 1998; 27 33-39
- 8 Schüler P, Zemper K, Borner K, Koeppe P, Schaberg T, Lode H. Penetration of sparfloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. Eur Respir J. 1997; 10 1130-1136
- 9 Wise R. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy. Clin Drug Invest. 1999; 17 365-387
- 10 Lode H, Höffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P, Sievers B, Reimnitz D, Borner K, Koeppe P. Comparative pharmacokinetics of new quinolones. Drug. 1987a; 34 (Suppl 1) 21-25
- 11 Lode H, Höffken G, Olschewski P, Sievers B, Kirch A, Borner K, Koeppe P. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother. 1987b; 31 1338-1342
- 12 Davis R, Bryson H M. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs. 1994; 47 677-700
- 13 Montay G. Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review. J Antimicrob Chemother. 1996; 37 (Suppl A) 27-39
- 14 Efthymiopoulos C, Bramer S L, Maroli A. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. Clin Pharmacokinet. 1997a; 33 (Suppl 1) 1-8
- 15 Efthymiopoulos C, Bramer S L, Maroli A, Blum B. Theophylline and warfarin interaction studies with grepafloxacin. Clin Pharmacokin. 1997b; 33 (Suppl 1) 39-46
- 16 Barman Balfour J A, Wiseman L R. Moxifloxacin. Drugs. 1999; 57 363-373
- 17 Stass H. Metabolism and excretion of moxifloxacin. Drugs. 1999b; 58 (Suppl) 16-17
- 18 Chodosh S, McCarty J, Farkas S, Drehobl M, Tosiello R, Shan M, Aneiro L, Kowalsky S. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis. 1999a; 27 722-729
- 19 Chodosh S, Schreurs A, Siami G, Barkman H W, Anzueto A, Shan M, Moesker H, Stack T, Kowalsky S. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis. 1999b; 27 730-738
- 20 Reinert R R, Queck A, Kaufhold A, Kresken M, Lutticken R. Antimicrobial resistance and type distribution of Streptococcus pneumoniae isolates causing systemic infections in Germany, 1992 - 1994. Clin Infect Dis. 1995; 21 1398-1401
- 21 Momme¿ja-Marin H, Carbon C. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections. Drugs. 1999; 57 851-853
- 22 Chen D K, McGeer A, Azavedo J C, Low D E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. New Engl J Med. 1999; 341 233-239
- 23 Stahlmann R, Lode H. Nebenwirkungen der neueren Fluorchinolone. Arzneimitteltherapie. 1998a; 16/12 385-394
- 24 Stahlmann R, Lode H.
Safety overview. Toxicity, adverse effects, and drug interactions . In: Andriole VT (Hrsg) The Quinolones. San Diego et al; Academic Press 1998c: 369-415MissingFormLabel - 25 Langan C E, Cranfield R, Breisch S, Pettit R. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother. 1997; 40 (Suppl A) 63-72
- 26 Chodosh S, Lakshminarayan S, Swarz H, Breisch S. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. Antimicrob Agents Chemother. 1998; 42 114-120
- 27 Shah P M, Maesen F P, Dolmann A, Vetter N, Fiss E, Wesch R. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. J Antimicrob Chemother. 1999; 43 529-539
- 28 Höffken G, Meyer H P, Sprenger K, Verhoef L, . The CAP 1 Study Group . Efficacy and safety of moxifloxacin (MFX) vs. clarithromycin (CLR) for the treatment of community-acquired pneumonia (CAP). J Antimicrob Chemother. 1999; 44 (Suppl A) 390
- 29 Stahlmann R, Lode H. Toxicity of quinolones. Drugs. 1999; 58 (Suppl 2) 39-44
- 30 Christ W, Esch B. Adverse reactions to fluoroquinolones in adults and children. Inf Dis Clin Pract. 1994; 3 (Suppl 3) 168-176
- 31 Bowie W R, Willetts V, Jewesson P J. Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin. Antimicrob Agents Chemother. 1989; 33 1778-1782
- 32 Vincent J, Agin M, Laboy-Goral L, Hunt T, Carlson J, Apseloff G, Kuye O. Effect of dosing with food and bedtime dosing on the incidence of dizziness/lightheadedness
with trovafloxacin in young, healthy, female subjects. ICAAC 1998 Poster A-086
MissingFormLabel
- 33 NN 1999. Trovafloxacin. Z Chemother 1999 20: 30-31 (oder www.zct-berlin.de, Neueinführungen, Trovafloxacin)
MissingFormLabel
- 34 Stahlmann R, Lode H. Safety of quinolones. The Lancet. 1998b; 352/9136 1313 (Letter)
- 35 Carrasco J M, Gacia B, Andujar C, Garrote F, Juana P, Bermejo T. Tendinitis associated with ciprofloxacin. Ann Pharmacother. 1997; 31 120 (Letter)
- 36 Kahn M F, Hayem G. Tendons and fluoroquinolones - unresolved issues. Rev Rhum (Engl Ed). 1997; 64 437-439
- 37 Shakibaei M, Pfister K, Schwabe R, Stahlmann R. Effects of ofloxacin on the ultrastructure of Achilles tendon in rats. Drugs. 1999; 58 (Suppl 2) 390-392
- 38 Lode H. Drug interactions with quinolones. Rev Infect Dis. 1988; 10 (Suppl 1) 132-136
- 39 Janknegt R. Drug interactions with quinolones. J Antimicrob Chemother. 1990; 26 (Suppl D) 7-29
- 40 Stahlmann R, Deppermann K-M, Schulz-Schalge T, Lode H. Klinisch relevante Arzneimittel-Interaktionen während einer Behandlung mit Chinolonen. Chemother J. 1992; 1/1 7-10
- 41 Nix D E.
Drug-drug interactions with fluoroquinolone antimicrobial agents . In: Hooper, DC, Wolfson, JS (eds) Quinolone Antimicrobial Agents. Washington; Am Soc Microbiol 1993: 245-258MissingFormLabel - 42 Höffken G, Borner K, Glatzel P D, Koeppe P, Lode H. Reduced internal absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol. 1985; 4 345
- 43 Höffken G, Lode H, Wiley R, Glatzel T D, Sievers D, Olschewski T, Borner K, Koeppe P. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effect of food and antacid intake. Rev Infect Dis. 1988; 10 (Suppl 1) 138-139
- 44 Deppermann K M, Lode H. Fluoroquinolones. Interaction profile of central absorption. Drugs. 1993; 45 (Suppl 3) 65-72
- 45 Sahai J, Gallicano K, Oliveras L, Khaliq S, Hawley-Foss N, Garber G. Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther. 1993; 53 292-297
- 46 Garrelts J C, Godley P J, Peterie J D, Gerlach E H, Yakshe C C. Sucralfate significantly reduces ciprofloxacin concentrations in serum. Antimicrob Agents Chemother. 1990; 34 931-933
- 47 Kawai Y, Matsubayashi K, Hakusui H. Interactions of quinolones with metal cations in aqueous solution. Chem Pharm Bull. 1996; 44 1425-1430
- 48 Stass H, Wandel C. No significant interaction between oral moxifloxacin (MOX) and calcium supplements (CAS) in healthy volunteers (HV). J Antimicrob Chemother. 1999; 44 (Suppl A) 416
- 49 Neuvonen P J, Kivistö K T, Lehto P. Interference of dairy products with the absorption of ciprofloxacin. Clin Pharmacol Ther. 1991; 50 498-502
- 50 Stass H. Absorption and bioavailability of moxifloxacin. Drugs. 1999a; 58 (Suppl) 14-15
- 51 Polk R E, Healy D P, Sahai J, Drwal L, Racht E. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother. 1989; 33 1841-1844
- 52 Lomaestro B M, Bailie G R. Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1991; 35 1004-1007
- 53 Palu¿ G, Valisena S, Ciarrocchi G, Gatto B, Palumbo M. Quinolone binding to DNA is mediated by magnesium ions. Proc Natl Acad Sci USA. 1992; 89 9671-9675
- 54 Wijnands W J, Herwaarden C L, Vree T B. Enoxacin raises plasma theophylline concentrations. The Lancet. 1984; 2 108-109
- 55 Maesen F PV, Teengs J P, Baur C, Davies B I. Quinolones and raised plasma concentrations of theophylline. Lancet. 1984; 2 530
- 56 Davies B I, Maesen F PV, Teengs J P. Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study. J Antimicrob Chemother. 1984; 14 (Suppl C) 83-89
- 57 Wijnands W J, Vree T B, Herwaarden C L. The influence of quinolone derivates on theophylline clearance. Br J clin Pharmacol. 1986; 22 677-683
- 58 Stille W, Harder S, Mieke S, Beer C, Shah P M, Frech K, Staib A H. Decrease of caffeine elimination in man during co-administration of 4-quinolones. J Antimicrob Chemother. 1987; 20 729-734
- 59 Healy D P, Polk R E, Kanawati L, Rock D T, Mooney M L. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother. 1989; 33 474-478
1 Herrn Prof. Dr. H. Lode zum 60. Geburtstag gewidmet
Ralf Stahlmann
Institut für Klinische Pharmakologie und Toxikologie
Abt. Toxikologie
Freie Universität Berlin
Garystraße 5
D-14195 Berlin